文献速递乳腺癌

I至III期激素受体阳性乳腺癌男性患者20年死亡风险

Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

该观察性队列研究基于监测、流行病学和最终结果(SEER)项目数据,纳入1990至2008年诊断的2836例I至III期激素受体阳性乳腺癌男性,中位随访15.41年。结果显示乳腺癌特异性死亡(BCSM)20年累积风险随分期升高:I期12.4%、II期26.2%、III期46.0%,且BCSM风险持续至少20年,与年龄、分期、分级相关。

要点

  • 男性I至III期激素受体阳性乳腺癌20年BCSM累积风险:I期12.4%、II期26.2%、III期46.0%。
  • 诊断后存活5年的患者中,年龄<50岁较>64岁、分级II或III/IV较I级、分期II或III较I期的调整后BCSM风险更高。
  • N3和III期患者的BCSM风险呈双峰分布,危险率峰值分别出现在第4年和第11年。

核心结论

  • 在I至III期激素受体阳性乳腺癌男性中,BCSM风险持续至少20年,并取决于年龄、肿瘤分期和肿瘤分级等传统临床病理因素。
  • 在分期较高的男性患者中,BCSM风险的动力学似乎与女性中已报告的风险不同。

研究设计与样本

  • 观察性队列研究,使用监测、流行病学和最终结果(SEER)项目的基于人群数据,纳入1990至2008年诊断的I至III期激素受体阳性乳腺癌男性。
  • 共纳入2836例男性,中位随访15.41年(IQR 12.08-18.67),诊断时中位年龄67岁(IQR 57-76)。
  • 采用累积发生率函数估计基線临床病理变量与BCSM及非BCSM累积风险的关系,绘制BCSM随时间变化的平滑风险估计,并用Fine和Gray多变量回归评估预选变量与BCSM的关联(条件为存活5年)。

主要发现

  • BCSM的20年累积风险:I期12.4%、II期26.2%、III期46.0%。
  • BCSM的平滑年风险估计显示,随着淋巴结分类递增,晚期危险率增加,在N3和III期达到双峰分布,两者危险率峰值分别在第4年和第11年。
  • 诊断后存活5年的患者中,调整后BCSM风险:年龄<50岁 vs >64岁更高,分级II或III/IV vs I级更高,分期II或III vs I期更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In women with hormone receptor-positive (HR+) breast cancer, the risk of distant recurrence and death persists for at least 20 years from diagnosis. The risk of late mortality in men with HR+ breast cancer has not been reported. OBJECTIVE: To report 20-year risks of breast cancer-specific mortality (BCSM) and non-BCSM in men with stage I to III HR+ breast cancer and identify factors associated with late BCSM. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study was conducted of men diagnosed with HR+ breast cancer from 1990 to 2008, using population-based data from the Surveillance, Epidemiology, and End Results program. Men diagnosed with stage I to III HR+ breast cancer were included in the analysis. Cumulative incidence function was used to estimate the outcomes of baseline clinicopathologic variables regarding cumulative risk of BCSM and non-BCSM since diagnosis. Smoothed hazard estimates over time were plotted for BCSM. Fine and Gray multivariable regression evaluated the association of preselected variables with BCSM, conditional on having survived 5 years. MAIN OUTCOME MEASURE: BCSM. RESULTS: A total of 2836 men with stage I to III HR+ breast cancer were included, with a median follow-up of 15.41 (IQR, 12.08-18.67) years. Median age at diagnosis was 67 (IQR, 57-76) years. The cumulative 20-year risk of BCSM was 12.4% for stage I, 26.2% for stage II, and 46.0% for stage III. Smoothed annual hazard estimates for BCSM revealed an increase in late hazard rates with each incremental node category, reaching a bimodal distribution in N3 and stage III, with each having peaks in hazard rates at 4 and 11 years. Among patients who survived 5 years from diagnosis, the adjusted BCSM risk was higher for those younger than 50 years vs older than 64 years, those with grade II or III/IV vs grade I tumors, and stage II or III vs stage I disease. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that, in men with stage I to III HR+ breast cancer, the risk of BCSM persists for at least 20 years and depends on traditional clinicopathologic factors, such as age, tumor stage, and tumor grade. Among men with higher stages of disease, the kinetics of the BCSM risk appear different from the risk that has been reported in women.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Leone J, Hassett MJ, Freedman RA, et al. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024. PMID: 38421673. doi:10.1001/jamaoncol.2023.7194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。